The increase in sales projection for TrinScreen HIV indicates strong demand, which is a positive indicator for future revenue growth. Additionally, the expansion of manufacturing capacity suggests the company is well-positioned to meet increased demand, particularly in response to the WHO Mpox emergency. These factors are likely to positively impact Trinity Biotech's stock price in the short term.